FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Diltiazem Hydrochloride
Status: Currently in Shortage
»Date first posted: 02/21/2018
»Therapeutic Categories: Cardiovascular

Expand all

Akorn Pharmaceuticals (Revised 07/30/2018)

Company Contact Information:
800-932-5676

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10) Short supply, on allocation. Recovery estimated in December 2018. Demand increase for the drug
Diltiazem HCl Injection (Premier) 25 mg / 5 mL, 10 mL, 10 vials (NDC 17478-0817-10) Short supply, on allocation. Will not produce further batches of this NDC#. Demand increase for the drug
Diltiazem HCl Injection (Premier) 5 mg / mL, 25 mL, 1 vial (NDC 17478-0817-25) Backordered. Batch release 8/3 will fill backorders. Will not produce further batches of this NDC#. Demand increase for the drug
Diltiazem HCl Injection (Premier) 5 mg / mL, 25 mL, 10 vials (NDC 17478-0817-26) Backordered. Will not produce further batches of this NDC#. Demand increase for the drug
Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25) Backordered. Batch release on 8/3 will partially fill back order. Recovery estimated in December 2018. Demand increase for the drug
Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26) Backordered. Recovery estimated in December 2018. Demand increase for the drug
Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05) Short supply, on allocation. Batch release on 8/3 will partially fill back order. Recovery estimated in December 2018. Demand increase for the drug
Diltiazem HCl Injection (Premier) 0.5 mg / mL, 30 gram, 10 vials (NDC 17478-0817-05) Short supply, on allocation. Batch release on 8/10 will fill back order. Will not produce further batches of this NDC#. Demand increase for the drug

Hospira, Inc. (Revised 08/08/2018)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03) Next Delivery: August 2018; Estimated Recovery: 2019 Demand increase for the drug
25 mg/5 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-01) Next Delivery and Estimated Recovery: 2019 Shortage per Manufacturer: Manufacturing Delay Other
50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02) Next Delivery and Estimated Recovery: 2019 Shortage per Manufacturer: Manufacturing Delay Other

West-Ward Pharmaceuticals (Revised 08/02/2018)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
5 mg/mL, 5 mL vial (NDC 0641-6013-10) This presentation is temporarily on backorder. Additional lots are scheduled to be manufactured in the September 2018 timeframe. Product will be made available as it is released. Demand increase for the drug
5 mg/mL, 10 mL vial (NDC 0641-6014-10) This presentation is temporarily on backorder. Additional lots are scheduled to be manufactured in the September - October 2018 timeframe. Product will be made available as it is released. Demand increase for the drug
5 mg/mL, 30 mL vial (NDC 0641-6015-10) This presentation is temporarily on backorder. Additional lots are scheduled to be manufactured in the August 2018 timeframe. Product will be made available as it is released. Demand increase for the drug

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English